Correction to: Rifamycin SV MMX[®]: A Review in the Treatment of Traveller's Diarrhoea

Sheridan M. Hoy¹

Published online: 20 June 2019
© Springer Nature Switzerland AG 2019

Correction to: Clinical Drug Investigation
<https://doi.org/10.1007/s40261-019-00808-2>

The original version of this article unfortunately contained a mistake. The corrected details are given below.

In Sect. 5 “Tolerability of Rifamycin SV MMX[®]”, the first sentence of the second paragraph should read as:

In the placebo-controlled study, the incidence of treatment-emergent adverse events (TEAEs) did not significantly differ between the rifamycin SV MMX[®] ($n = 199$) and placebo ($n = 65$) groups (29.6 vs. 38.5% of patients) [13], with most TEAEs considered to be unrelated to the study medication.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s40261-019-00808-2>.

✉ Sheridan M. Hoy
demail@springer.com

¹ Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand